Equities

APOLLO BioWellness Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
KOAN:PKC

APOLLO BioWellness Inc

Actions
  • Price (USD)0.0025
  • Today's Change0.00 / 0.00%
  • Shares traded1.28m
  • 1 Year change+78.57%
  • Beta3.8115
Data delayed at least 15 minutes, as of Feb 12 2026 19:36 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. The Company is engaged in the field of regenerative medicine using biologic-based products. Its products are intended to market under third-party label exemptions. The Company is focused on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. It is licensed under a patent-pending application to market a dual-acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Its products are being developed for consumer and professional markets.

  • Revenue in USD (TTM)2.23m
  • Net income in USD-2.00m
  • Incorporated2013
  • Employees6.00
  • Location
    APOLLO BioWellness Inc26565 AGOURA RD.,, SUITE 200,CALABASAS 91302United StatesUSA
  • Phone+1 (571) 888-0009
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Neutra Corp66.08k-177.83k304.29k--------4.60-0.00006-0.000060.00002-0.00032.42-------652.23-401.90----64.32---269.11-1,234.68---38.69-----41.87--59.53------
Altamira Therapeutics Ltd0.00-5.65m542.97k13.00--0.1333-----1.45-1.450.000.71280.00----0.00-74.38-74.95-96.95-118.32------------0.1624-------4.53---49.17--
Grapefruit USA Inc34.85k-4.37m569.35k9.00------16.34-0.008-0.0080.00006-0.01010.01211.310.22593,872.22-151.85-268.93-----1,304.65-10.09-12,531.68-408.870.0388-1.50-----83.9677.87-35.68------
Apollo Biowellness Inc2.23m-2.00m640.09k6.00------0.2868-0.0189-0.01890.02-0.02160.6255-------56.14-371.95----65.5258.46-89.76-533.66---5.26----11,413.18---50.65------
Pure Harvest Corporate Group Inc2.48m-6.67m861.66k25.00--0.3823--0.3479-0.0901-0.09010.03830.02010.26441.4640.6499,070.40-70.96---136.76--33.83---268.37--0.5886-0.8660.7639--1,808.41---459.26------
ITonis Inc0.00-1.17m914.05k-----------0.0012-0.00120.00-0.00040.00-------187.63---1,169.36-------------0.8999---------506.86------
Vitalibis Inc243.57k-3.96m986.42k0.00------4.05-0.1103-0.11030.0034-0.00690.52010.352-----844.71-1,100.84----51.56---1,624.14-2,623.600.5512-2.33----490.69---207.18------
Evofem Biosciences Inc17.73m-5.56m1.14m32.00------0.0643-0.058-0.0580.0111-0.56610.93922.253.61553,937.50-28.79-177.41----80.0569.60-30.66-602.270.0797-0.2439----6.28---117.93---38.87--
Data as of Feb 12 2026. Currency figures normalised to APOLLO BioWellness Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.